Key result
Pitavastatin evaluated for anti-inflammatory effects measured by monocyte-to-HDL ratio.
Why the study?
Statins have anti-inflammatory pleiotropic effects alongside lipid-lowering properties, and the effect of pitavastatin therapy on the novel inflammation marker monocyte count to high-density lipoprotein cholesterol ratio (MHR) in patients with coronary heart disease needed examination.
Does lipid-lowering therapy with pitavastatin 4 mg/day reduce the monocyte count to HDL cholesterol ratio (MHR) in patients with stable coronary artery disease and hypercholesterolemia?
Cohort (n=150)
No
Does lipid-lowering therapy with pitavastatin 4 mg/day reduce the monocyte count to HDL cholesterol ratio (MHR) in patients with stable coronary artery disease and hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
In patients with stable coronary artery disease and hypercholesterolemia, pitavastatin 4 mg/day over a median of 3 months significantly improved serum lipid profiles (LDL-C, total cholesterol, triglycerides) but did not significantly lower the monocyte-to-HDL cholesterol ratio.
Objectives: Monocyte count to high-density lipoprotein cholesterol ratio (MHR) was proposed as a novel inflammation marker. Statins have some anti-inflammatory pleiotropic effects as well as lipid-lowering effects.This study aims to examine the effect of lipid-lowering therapy with pitavastatin on MHR in patients withcoronary heart disease.Methods: This was a descriptive study, single-center study. Hospital registries between October 2018 andApril 2019 were retrospectively reviewed. Eligible patients were those who had both stable coronary arterydisease and hypercholesterolemia of low-density lipoprotein cholesterol (LDL-C) >100 mg/dL and started totake treatment (pitavastatin, 4 mg/day). Pre-and post-treatment complete blood count values and lipid parameters were evaluated, and MHR was calculated.Results: This study enrolled 150 patients. Pitavastatin (4 mg/day) was administered throughout median 3.0(1.0-7.0) months. Mean total cholesterol level declined from 235.2±52.3 mg/dl to 186.9±48.8 mg/dl (p<0.001).Mean triglyceride level declined from 167.2±75.0 mg/dl to 152.8±66.7 mg/dl and mean LDL-C level declinedfrom 153.9±45.0 mg/dl to 109.0±41.2 mg/dl (p=0.020 and p<0.001, respectively). Moreover, pre-treatmentMHR declined from 1.4 (0.4-4.0) to post-treatment MHR 1.3 (0.5-3.4) (p=0.263).Conclusion: This study concluded that pitavastatin improved serum lipid levels but did not decrease MHR
No takes yet. Share an insight, caveat, or question.
Şeyda Günay (2020) conducted a cohort in Stable coronary artery disease and hypercholesterolemia (n=150). Pitavastatin vs. Pre-treatment baseline was evaluated on Monocyte count to high-density lipoprotein cholesterol ratio (MHR) (p=0.263). Pitavastatin /day lowered LDL-C from 153.9 to /dL without reducing MHR.
Synapse has enriched 10 related papers. Consider them for comparative context: